Polaris Partners

Noema Pharma to Attend and Present at Stifel 2022 CNS Days

Retrieved on: 
Friday, March 25, 2022
Trigeminal neuralgia, Company, Tourette syndrome, Seizure, Lists of diseases, Sofinnova, CNS, Tuberous sclerosis complex tumor suppressors, Glutamate (neurotransmitter), PDE10A, TSC, GLOBE, Polaris Partners, Patient, Pharmaceutical industry, Noema

BASEL, Switzerland, March 25, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical-stage company targeting orphan and large-market central nervous system (CNS) diseases, today announces it will participate in the Stifel 2022 CNS Days conference, being held virtually from March 28 to 29, 2022.

Key Points: 
  • BASEL, Switzerland, March 25, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical-stage company targeting orphan and large-market central nervous system (CNS) diseases, today announces it will participate in the Stifel 2022 CNS Days conference, being held virtually from March 28 to 29, 2022.
  • Management will also present the latest development of Noema to investors and will host 1:1 investor meetings.
  • Noema Pharma ( www.noemapharma.com ) is a Swiss-based company targeting neurological disorders characterized by imbalanced neuronal networks.
  • Noema Pharma was founded with the leading venture capital firm Sofinnova Partners.

Sonrai Security Adds Workload Security to Make it the Most Comprehensive Cloud Security Platform in the Market Today

Retrieved on: 
Tuesday, March 22, 2022
Data Management, Security, Technology, Software, Networks, Internet, Cloud, Adoption, Menlo Ventures, Map, Classification, Chief information security officer, Automation, ID, Platform as a service, CEO, Posture, Industry, NYCRR, Workflow, CSPM, Solution, Polaris Partners, Risk management, Video game console, Gartner, Songhai

Todays announcement expands Sonrais comprehensive cloud security platform that already incorporates Cloud Infrastructure Entitlements Management (CIEM), Cloud Security Posture Management (CSPM) and data security functionality.

Key Points: 
  • Todays announcement expands Sonrais comprehensive cloud security platform that already incorporates Cloud Infrastructure Entitlements Management (CIEM), Cloud Security Posture Management (CSPM) and data security functionality.
  • Sonrai Dig delivers a cloud security solution that unearths, prioritizes and removes risks across every part of a customer's public cloud.
  • Sonrai Security delivers enterprise cloud security for the public cloud.
  • Powered by our cloud identity graph, Sonrai combines workload, platform, identity, and data security in one platform.

Cohere Health Advises Federal Government on the Development of Electronic Prior Authorization Standards

Retrieved on: 
Tuesday, March 29, 2022
Adoption, X12, Office of the National Coordinator for Health Information Technology, CB Insights, EMR, Human services, CEO, Fast Healthcare Interoperability Resources, Scalable Coherent Interface, FHIR, Technology, Digital, Machine learning, United States Department of Health and Human Services, Physician, Department, Polaris Partners, History, ONC, Medical device, Health insurance, Health

BOSTON, March 29, 2022 /PRNewswire/ -- Cohere Health, a recognized leader in collaborative utilization management technology, announced that it has submitted recommendations to the Office of the National Coordinator for Health Information Technology (ONC) on the development of electronic prior authorization standards. Cohere urged ONC to help reduce the burden of adoption on providers by requiring electronic medical record (EMR) vendors to adopt ONC standards to drive a fully interoperable healthcare system.

Key Points: 
  • Cohere's intelligent authorization platform uses machine learning, interoperability, and advanced analytics to streamline the prior authorization process and accelerate patient access to high-value care.
  • Cohere also expressed support for the adoption of Fast Healthcare Interoperability Resources (FHIR) standard to simplify the administrative workflow in prior authorization.
  • "Transforming the prior authorization paradigm is a critical element of shifting our nation's healthcare system toward value-based care," said Siva Namasivayam, CEO of Cohere Health.
  • Cohere Health drives collaborative utilization management (UM) by aligning physicians and health plans on evidence-based care paths for the patient's entire care journey.

Podimetrics Secures $45 Million Series C To Help At-Risk Providers and Health Plans Prevent Diabetic Amputations in High-Risk Patients

Retrieved on: 
Thursday, March 24, 2022
Adoption, American Podiatric Medical Association, Hospital, Risk, Health equity, LinkedIn, Temperature, International Diabetes Federation, Ulcer, Diabetes, DFU, Death, Health, Multimedia, Virtus Investment Partners, Seal, Research, Veterans Health Administration, CEO, D1 Capital Partners, View, MD, Technology, Twitter, Inflammation, Amputation, Time, Smartmatic, FDA, African Americans, Polaris Partners, Patient, Foot, Plaster, Pharmaceutical industry, D1

SOMERVILLE, Mass., March 24, 2022 /PRNewswire/ -- Podimetrics, creator of the FDA-cleared SmartMat™ and integrated clinical care services that can help save the limbs and lives of complex patients with diabetes, today announced a $45 million Series C round led by D1 Capital Partners, along with two new investors, the Medtech Convergence Fund and an undisclosed strategic investor. Existing investors, Polaris Partners and Scientific Health Development, also participated in the financing. Prior to their Series C, Podimetrics had raised $28.3 million in funding to fuel development and distribution of their SmartMat.

Key Points: 
  • Prior to their Series C, Podimetrics had raised $28.3 million in funding to fuel development and distribution of their SmartMat.
  • This new funding will help even more at-risk providers and health plans drive broader adoption of Podimetrics' SmartMat so they can improve care outcomes for at-risk patients dealing with diabetic foot ulcers (DFUs) that often lead to amputations.
  • Podimetrics, founded in 2011, developed the SmartMat the only easy-to-use, at-home mat that a patient steps on for 20 seconds per day.
  • Through partnerships with regional and national health plans and at-risk providers, such as the Veterans Health Administration, Podimetrics has helped prevent amputations associated with complex diabetes.

TRexBio Completes $26 Million Series A Extension Led by Polaris Partners to Advance Treatments for Immune-Mediated Diseases

Retrieved on: 
Tuesday, March 8, 2022
Health, Other Science, Research, Pharmaceutical, Science, Biotechnology, Eli Lilly and Company, LinkedIn, Investment, Board, Company, Janssen Pharmaceuticals, Inflammation, Polaris Partners, Johnson & Johnson, Immune system, Therapy, Pharmaceutical industry, Regulatory T cell

TRexBio Inc. , a discovery stage company decoding human tissue immune biology to create revolutionary therapeutics, today announced it has completed a $26 million extension of its Series A financing in a round led by new investor Polaris Partners.

Key Points: 
  • TRexBio Inc. , a discovery stage company decoding human tissue immune biology to create revolutionary therapeutics, today announced it has completed a $26 million extension of its Series A financing in a round led by new investor Polaris Partners.
  • This brings the total Series A funding raised by TRexBio to $85 million.
  • TRexBio is working to redefine how immune-mediated diseases are treated, said Johnston Erwin, TrexBios CEO.
  • In conjunction with the financing, Alexandra Cantley, Ph.D., Partner at Polaris Partners will join the companys Board of Directors.

Tausight Unveils Industry’s First Situational PHI Awareness Platform Built for the Modern Healthcare Ecosystem

Retrieved on: 
Monday, March 7, 2022
Public Policy, Government, Healthcare Reform, General Health, Health, NLP, Risk, 21st Century Cures Act, Movement, Health care, Patient, MBA, Hospital, Policy, Baptist Health System, Health, Privacy, CTO, LinkedIn, Solution, Awareness, Vive, Efficiency, PHI, Computer security, Compliance, CEO, Maintenance, Learning, Polaris Partners, Telemetry, Software as a service, Medical imaging, Online shopping, Twitter

Tausight , the PHI detection company for healthcare, today unveiled the healthcare markets first automated, situational awareness platform to detect, track and analyze PHI activity and risk in real-time, anywhere in todays distributed healthcare ecosystem.

Key Points: 
  • Tausight , the PHI detection company for healthcare, today unveiled the healthcare markets first automated, situational awareness platform to detect, track and analyze PHI activity and risk in real-time, anywhere in todays distributed healthcare ecosystem.
  • Healthcare IT security teams have historically relied on data protection solutions built to lock data inside the firewall.
  • Tausights situational PHI awareness platform enables customers to:
    Mitigate risk across healthcares distributed care system Provides a comprehensive view into all PHI activity in a healthcare organizations data center and at every endpoint.
  • The Tausight platform ensures this level of streamlined access to PHI while providing peace of mind that private information stays secure.

Cohere Health Leaders Selected to Speak at ViVE Conference

Retrieved on: 
Tuesday, March 1, 2022
Population health, Laika (EHR testing framework), Entrepreneurship, Chief executive officer, Government, Physician, Red pill and blue pill, College of Healthcare Information Management Executives, Vive, Investment, Health, Revenue cycle management, SVP, Oscar Health, CB Insights, CHIME, Polaris Partners, Disruptive innovation, Digital, Multimedia, Machine learning, Health care, Leadership, College, Patient, AI, Technology, Communication, CEO, Medical device, Pharmaceutical industry, Management, Health insurance, Anomaly, Coherent, Inc.

BOSTON, March 1, 2022 /PRNewswire/ -- Cohere Health, a recognized leader in intelligent utilization management (UM) technology, announced that two of its senior leaders will speak at the inaugural ViVE conference March 6-9 in Miami Beach, FL. The company's executives will share their perspectives on how to use AI and machine learning to build patient-centered solutions that improve outcomes and reduce costs. Founded in 2019, Cohere drives collaborative UM by aligning patients, physicians, and health plans on evidence-based care paths at the point of care.

Key Points: 
  • BOSTON, March 1, 2022 /PRNewswire/ -- Cohere Health , a recognized leader in intelligent utilization management (UM) technology, announced that two of its senior leaders will speak at the inaugural ViVE conference March 6-9 in Miami Beach, FL.
  • Founded in 2019, Cohere drives collaborative UM by aligning patients, physicians, and health plans on evidence-based care pathsat the point of care.
  • In addition, Gina Kim, Cohere Health's Chief Product Officer, will speak at a panel discussion focused on the digital renaissance of revenue cycle management.
  • Cohere Health drives collaborative utilization management (UM) by aligning physicians and health plans on evidence-based care paths for the patient's entire care journey.

Noema Pharma Appoints Michael Gutch as Chief Financial Officer

Retrieved on: 
Monday, February 28, 2022
GLOBE, Therapy, Sofinnova, Board, Growth, Trigeminal neuralgia, Pain, State university system, NASDAQ, Â, Company, TSC, HIG, Safety, Noema, Glutamate (neurotransmitter), Polaris Partners, Corporate development, Tourette syndrome, Tuberous sclerosis complex tumor suppressors, Leadership, H.I.G. Capital, MBA, Patient, Eli Lilly and Company, PDE10A, Seizure, CNS, AstraZeneca, Pharmaceutical industry, Management, Entasis, Indiana University

BASEL, Switzerland, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of Michael Gutch, Ph.D., as Chief Financial Officer.

Key Points: 
  • BASEL, Switzerland, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of Michael Gutch, Ph.D., as Chief Financial Officer.
  • With his impressive background in healthcare and in senior transactional and operating roles, we look forward to the benefit of his leadership and wealth of experience," said Luigi Costa, Noema Pharma's Chief Executive Officer.
  • "Noema Pharma is making fantastic progress with the development of its clinical pipeline to bring its potentially transformative assets to patients with debilitating CNS conditions," said Michael Gutch, Noema Pharma's Chief Financial Officer.
  • Michael Gutch, Ph.D., joins Noema Pharma from Entasis Therapeutics, where he served as Chief Business Officer and Chief Financial Officer from 2017.

Noema Pharma announces first patient dosed in Phase 2b LibraTN study of mGluR5 inhibitor NOE-101 in trigeminal neuralgia

Retrieved on: 
Tuesday, February 22, 2022
GLOBE, Therapy, University of California, San Diego Performance-Based Skills Assessment, Nerve injury, Sofinnova, Pain management, Chronic pain, Partnership, Trigeminal nerve, Trigeminal neuralgia, Pain, Sensation, University, Company, TSC, Associate, Safety, Glutamate (neurotransmitter), Polaris Partners, Adult, Neuropathic pain, Tourette syndrome, Tuberous sclerosis complex tumor suppressors, Brain, Patient, PDE10A, Neurology, Solution, Face, Seizure, Pharmaceutical industry

BASEL, Switzerland, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system diseases, today announces the dosing of its first patient in its Phase 2b clinical trial of the mGluR5 inhibitor NOE-101 in trigeminal neuralgia (TN).

Key Points: 
  • BASEL, Switzerland, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system diseases, today announces the dosing of its first patient in its Phase 2b clinical trial of the mGluR5 inhibitor NOE-101 in trigeminal neuralgia (TN).
  • LibraTN is a multi-center, 24-week, prospective, double-blind, randomized-withdrawal, placebo-controlled study to evaluate the efficacy and safety of NOE-101 in adults with pain associated with TN.
  • "It's very exciting to have dosed our first patient in this Phase 2b trial in trigeminal neuralgia.
  • Lead product NOE-101, an mGluR5 inhibitor, is currently evaluated in pain associated with Trigeminal Neuralgia (TN) and in seizures in Tuberous Sclerosis Complex (TSC).

Kallyope Raises $236M Series D Financing to Fuel Expansion of Novel Gut-Brain Axis Therapeutic Programs

Retrieved on: 
Tuesday, February 15, 2022
Biotechnology, General Health, Health, Science, Research, Tao, Health, CEO, Type 2 diabetes, Science, Research, Doctor of Philosophy, Brain, Research and development, DN Capital, List of life sciences, Nobel, Molecular biology, Gastrointestinal tract, Development, Leadership, Investment, Therapy, Neurological disorder, Mubadala Investment Company, StepStone Group, Disease, Head, Inflammation, Lux Capital, Drug discovery, Genetics, Probability, Polaris Partners, Obesity, Nicholas J. Pritzker, Metabolism, Pharmaceutical industry, Growth

Since our inception six years ago, Kallyope has pioneered research on the gut-brain axis and developed a transformational drug discovery platform with speed and ingenuity.

Key Points: 
  • Since our inception six years ago, Kallyope has pioneered research on the gut-brain axis and developed a transformational drug discovery platform with speed and ingenuity.
  • We are now positioned at the forefront of this space, said Jay Galeota, president and CEO, Kallyope.
  • Kallyope has built a highly original platform that integrates several sophisticated technologies for the discovery and translation of gut-brain biology.
  • Kallyope has raised nearly $480 million to date, including a $112 million Series C financing in March 2020.